I can only venture a guess that it MIGHT be a 4-hydroxy - MDMA. Send them an email and ask them. Regards PDB PMMA I have no clue whatsoever. I hope it nothing like PMA, which has sickened and killed quite a few people.
If this bunch does not answer an email, you certainly do not want to do any business with them. Without naming names outside of the sources forum, do let us know what they have to say - or not say.
"The effects of 3,4-methylenedioxymethamphetamine (MDMA or 'ecstacy') and two structurally related compounds, N-methyl-1-(3,4-methylenedioxyphenyl)-1-ethanamine (MDM1EA) and N-methyl-1-(3,4-methylenedioxyphenyl)-3-butanamine (HMDMA) were examined in two preparations: (i) a drug discrimination procedure in MDMA-trained rats and (ii) the chicken embryo, for determination of the direct effects of these compounds on the developing organism. The highest doses of MDM1EA and HMDMA partially substituted for MDMA, whereas higher (30-60 mg/kg) doses of HMDMA evoked clonic seizures in a separate group of rats. In chicken embryos MDMA had no effect on body, brain or liver weight, while the highest dose of MDM1EA decreased body weight and the 2 lowest doses of HMDMA increased body weight. All doses of HMDMA decreased liver weight (expressed as % body weight) when compared with contemporaneous water-treated controls. Taken together, the results of these experiments suggest that structurally related compounds share some stimulus properties with MDMA and may therefore share abuse liability. Furthermore, both MDMA-related compounds produced adverse effects on the developing organism, whereas MDMA did not."
PMMA is related to PMA, making it very dangerous. Shulgin says of PMA: "...the effects of PMA? At low levels, a seductive psychotropic buzz. Nice. At slightly higher levels, the clear effects of heart stimulation and blood pressure rise. Not nice. There have been reports of deaths associated with the use of PMA.
Alfa already has upload some precious informations about HMDMA higher. This is what was founded as an locked document on the web. To see the original text here is the link: http://jhs.pharm.or.jp/data/52(6)/52_805.pdf
Identification of N-Methyl-4-(3,4-Methylenedioxyphenyl) Butan-2-Amine, Distributed as MBDB
N-Methyl-4-(3,4-Methylenedioxyphenyl) Butan-2-Amine (MDP-2-MB, MBDB) is a new homologue of N-Methyl-1-(3,4-methylenedioxyphenyl)propan-2-amine (MDMA), which is strictly controlled as a narcotic. As part of a continuous survey on illegal designer drugs in the market, it was founded that N-Methyl-4-(3,4-Methylenedioxyphenyl)Butan-2-Amine (MDP-3-MB, HMDMA) was being sold as MBDB in Japan. As this is the first time that HMDMA has been revealed to be in market distribution, and its physic-chemical data is thus far unreported, there is a description of the structure elucidation of HMDMA and comparative analysis with related compounds.
As part of the continuous survey on illegal drugs, a phenylbutanamine derivative was found which is distinct from MBDB, although the drug may be labeled as containing MBDB. After spectroscopic analysis, the structure was identified as N-Methyl-4-(3,4-Methylenedioxyphenyl) Butan-2-Amine (MDP-3-MB, HMDMA). This could be the first time that HMDMA has been shown to be in market distribution, although several reports have described its pharmacological activity and analytical methods.
Little is known about the hallucinogenic activity of HMDMA, but some qualitative differences in pharmacological activity have been observed. Davis and Borne have compared the acute toxicities of MDa and MDMA with those of 4-(3,4-Methylenedioxyphenyl) Butan-2-Amine (HMDA) and HMDMA. They found that HMDA and HMDMA were equal or greater in toxicity than MDA and MDMA in mice, suggesting that HMDA and HMDMA constitute no less of hazard for acute toxicity in humans than MDA. Bronson et al. examined the effects of d-amphetamine and the designer drugs MDMA, HMDMA, in chick embryos and young chickens. HMDMA had no effects on moility but produced effects such as tremor, flat body posture, loss of righting reflex and liver weight reduction. They also reported that the higher doses (30-60 mg/kg) of HMDMA elicited clonic seizures in rats. Physico-chemical data for HMDMA has not been reported. Anaalytical procedure for HMDMA has been reported only by Noggle et al. N-substituded 4-(3,4-Methylenedioxyphenyl) Butan-2-Amines were separated via reversed-phase liquid chromatographic methods, partially based on comparative analysis with MDA, and the electron impact mass spectra of these compounds were determined using a capillary gas chromatography-mass spectrometry (GC-MS) system.
In this study there is a deal with the structural identification of HMDMA by spectroscopic analysis. In addition, there are a comparative analyses of HMDMA and related substances Amphetamine, Methamphetamine, MDA, MDMA, MDEA, MBDB and Methylone.
Analyses of Phenylalkylamines
Simon, Marquis and mandolin reagents were used for color tests to discriminate between the individual samples. MDA, MDMA, MDEA, MBDB and HMDMA take on a similar colors to those of the reagents used because they do not have distinctive functional groups. It was noted that methylone, which possesses a carbonyl group, showed a unique color (Table 1).
In the TLC experiment, eight samples showed the Rf values listed in table 2. It was difficult to discriminate MDMA from HMDMA using the solvent system A because of the similarity of their Rf values, as was the case for Amphetamine, MDA, MDEA and MBDB using the solvent system B. These results suggest that the standard material of HMDMA is needed to distinguish it from other designer drugs in primary surveillance with the color test ant TLC.
Ethyl acetate solutions of free base samples were used for GC-MS measurement. Each sample was well resolved under the conditions
described (Fig. 3) with specific fragments, ethylamine (m/z 44), N-methylethylamine (m/z 58), diethylamine or N-methylpropylamine (m/z 72), and 3,4-methylenedioxybenzyl (m/z 135) groups (Table 3), although the corresponding molecular ions were not observed.
Linear Mode
